*MEDICINE* GLP-1's (excluding those combined with insulin)

[a-d-brown]

User Requirements Identify patients who are taking a GLP-1 mimetic (excluding products which are combined with insulin). This will be used to identify assess the impact of the impact of GLP-1s being prescribed for weight loss.

Search Terms Antidiabetic drugs

Inclusion Criteria for Codes

• Refers to a GLP-1 mimetic without insulin in combination.

Exclusion Criteria for Codes

• Refers to a GLP-1 mimetic with insulin in combination.
• Refers to an antidiabetic drug which is not a GLP-1 mimetic.

Borderline Cases to Highlight

• Albiglutide - can be ignored as withdrawn from market, no longer available.
• Tirzepatide - this drug is an agonist of both GIP and GLP-1 receptors. I think it's probably still ok to class it with the pure GLP-1 agonists given that the overall effect of agonising either receptors is similar, i.e. to promote insulin secretion. Currently only 1 prescription in past 12m, but NICE are expected to issue guidance on its use in Oct23. Included in the codelist now to help futureproof it.

Codelist https://www.opencodelists.org/codelist/user/Andrew/glp-1s-excluding-those-combined-insulin/34f8ec89/#tree

[chrisjwood16]

Happy to approve this. Probably worth mentioning this list of GLP-1s includes those licensed only for weight loss (Saxenda). Also worth setting a reminder to review regularly as Wegovy is due to launch at some point this year.

[a-d-brown]

Thanks, I'll make sure to point out the licencing in the metadata description.

Final dm+d codelist: https://www.opencodelists.org/codelist/user/Andrew/glp-1s-excluding-those-combined-insulin-dmd/1e9c394a/